Background: The risk of bacterial contamination and the deterioration of platelet (PLT) quality limit the shelf-life of platelet concentrates (PCs). The INTERCEPT pathogen inactivation system reduces the risk of pathogen transmission by inhibiting nucleic acid replication using a combination of a photo-reactive compound and UVA illumination. The goal of this study was to investigate the effects the INTERCEPT system has on the PLT metabolome and metabolic activity.
Study Design And Methods: Paired units of buffy coat-derived PCs were generated using a pool and split strategy (n = 8). The paired PCs were either treated with the INTERCEPT system or left untreated. Samples were collected on Days 1, 2, 4, and 7 of storage. Ultra-performance chromatography coupled with time-of-flight mass spectrometry was used to analyze the extra- and intracellular metabolomes. Constraint-based metabolic modeling was then used to predict the metabolic activity of the stored PLTs.
Results: A relatively large number of metabolites in the extracellular environment were depleted during the processing steps of the INTERCEPT system, in particular, metabolites with hydrophobic functional groups, including acylcarnitines and lysophosphatidylcholines. In the intracellular environment, alterations in glucose and glycerophospholipid metabolism and decreased levels of 2-hydroxyglutarate were observed following the INTERCEPT treatment. Untargeted metabolomics analysis revealed residual amotosalen dimers present in the treated PCs. Systems-level analysis of PLT metabolism indicated that the INTERCEPT system does not have a significant impact on the PLT energy metabolism and nutrient utilization.
Conclusions: The INTERCEPT system significantly alters the metabolome of the stored PCs without significantly influencing PLT energy metabolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.15610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.
Cardiovasc Diabetol
January 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and function and/or abnormal cardiac biomarker concentrations.
Objective: To compare the evolution of four DbMD groups based on biomarkers alone, systolic and diastolic dysfunction alone, or their combination.
Implementation and evaluation of a novel community-based urban mobile health clinic in Toronto, Ontario.
Can J Public Health
January 2025
University Health Network, Toronto, ON, Canada.
Setting: Despite Canada's single-payer health system, marginalized populations often experience poor health outcomes and barriers to healthcare access. In response, mobile health clinics (MHCs) have been deployed in several cities across Canada. MHCs are well established in the United States; however, little is known about their role and impact in a country with universal healthcare.
View Article and Find Full Text PDFIndividual Sensitivity for Radiotherapy-related Adverse Tissue Reactions in Patients Treated Twice for Metachronous Cancers.
Radiat Res
January 2025
Department of Molecular Biosciences, Stockholm University, Stockholm, Sweden.
The role of genetics in susceptibility to radiotherapy-induced toxicities is unclear. A strong impact of genetics should cause correlated toxicities in patients with metachronous double radiotherapy. We ascertained information about demographics, lifestyle, radiotherapy and early toxicities in irradiated tissues for a retrospective cohort of 98 patients from 2 hospitals who underwent two metachronous radiotherapeutic treatments (2007-2022) of different anatomical regions.
View Article and Find Full Text PDFVirological Response to Lamivudine and Tenofovir Treatment in a Mono-infected Chronic Hepatitis B Patient with Potential Tenofovir Resistance: A Case Report.
J Clin Transl Hepatol
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Few cases of tenofovir resistance have been reported, and the appropriate treatment for such cases remains unclear. We aimed to share a case of a chronic hepatitis B mono-infected patient with potential tenofovir resistance who required combined lamivudine and tenofovir therapy to achieve adequate viral suppression. The patient's viral load (plasma) was monitored using the cobas® hepatitis B virus Test on the cobas® 6800 system.
View Article and Find Full Text PDFHarnessing advanced hybrid deep learning model for real-time detection and prevention of man-in-the-middle cyber attacks.
Sci Rep
January 2025
Department of Electronics and Communication Engineering, Panimalar Engineering College, Chennai, India.
Article Synopsis
- The increasing use of connected devices in smart homes has heightened security risks, particularly from Man-in-the-Middle (MitM) attacks, which can go undetected.
- Traditional security methods struggle to manage these complex threats, highlighting the need for more advanced intrusion detection systems.
- The AEXB Model, a hybrid deep learning approach combining AutoEncoder for feature extraction and XGBoost for classification, achieves 97.24% accuracy in detecting MitM attacks, while also enabling real-time threat responses and continuous protection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!